Yes, Europeans live significantly longer than Americans. According to preliminary 2024 data from Eurostat, life expectancy at birth in the European Union is 81.7 years. In the United States, that figure sits around 79 years, placing it 46th among 100 nations. That gap of roughly three years has persisted for decades, and it reflects deep structural differences in how people in each region live, die, and access care.
How Big Is the Gap?
The EU average of 81.7 years masks wide variation across the continent. The top performers are Italy and Sweden, both at 84.1 years, followed closely by Spain at 84.0. On the lower end, Bulgaria (75.9 years), Romania (76.6), and Latvia (76.7) fall below the EU average and closer to the American number. So the honest answer is that Americans live shorter lives than most Western and Northern Europeans, but roughly on par with some Eastern European countries.
A subtler measure tells an even starker story. Healthy life expectancy, which counts only years lived free from serious disease and disability, shows the Americas region at 63.2 years in 2021 compared to 66 years for the WHO European region. That means Europeans don’t just live longer; they spend more of their lives in good health. The European figure improved by about 3 years since 2000, while the Americas region actually declined slightly over the same period.
Younger Americans Die at Higher Rates
A major reason for the gap is that Americans are far more likely to die young. Heart disease and cancer account for 46% of all U.S. deaths, which is similar to European patterns. But at younger ages, a different set of causes dominates: suicide, gun violence, motor vehicle crashes, drug overdoses, and other injuries. These deaths cut decades off individual lifespans and drag down the national average disproportionately.
The numbers are striking. The U.S. firearm homicide rate is 4.5 per 100,000 people. That’s 77 times higher than Germany’s rate and 19 times higher than France’s. Even New Hampshire, the safest U.S. state for gun homicides, has a rate three times higher than Cyprus, the worst in Europe. In 2024, drug overdoses killed 79,384 Americans, a rate of 23.1 per 100,000. No European country comes close to that figure. These are deaths concentrated among people in their 20s, 30s, and 40s, which makes their impact on average life expectancy especially large.
Obesity and Chronic Disease
The U.S. has roughly double the obesity rate of Europe. About 37.5% of American men and 39.5% of American women are obese, compared to European rates that range from around 20% to 31% depending on the country (the UK being the highest in Europe). Obesity is a primary driver of type 2 diabetes, cardiovascular disease, and several cancers, all of which shorten life and reduce quality of life in later years.
This difference compounds over a lifetime. Higher obesity rates feed into higher rates of chronic disease, which in turn increase healthcare costs while worsening outcomes. Europe is not immune to rising obesity, but the baseline difference remains substantial.
Infant Mortality Adds to the Gap
The U.S. infant mortality rate has historically been about double that of top-performing European countries. Between 2000 and 2005, the U.S. rate was 6.78 deaths per 1,000 live births, compared to 3.21 in Finland, 3.98 in Austria, and 4.40 in Belgium. Even after restricting the comparison to similar birth weights and gestational ages, normal-weight American infants died at a rate of 2.3 per 1,000, while Finnish and Austrian rates were 1.5 and 1.3 respectively.
Infant deaths have an outsized effect on life expectancy calculations because each one represents an entire lifetime lost. The gap narrows somewhat when researchers control for differences in how countries record extremely premature births, but a real disadvantage remains, particularly in the postneonatal period (one month to one year), when access to healthcare and social support matters most.
Spending More, Getting Less
The U.S. spends far more on healthcare than any European country. In 2019, American healthcare spending hit 16.7% of GDP, nearly double the OECD average of 8.7%. Per capita pharmaceutical spending alone was $1,277 that year, the highest among industrialized nations. Yet this spending does not translate into better outcomes.
One way to measure this is through “amenable mortality,” deaths from treatable conditions like diabetes and appendicitis that shouldn’t be fatal with timely care. Between 1999 and 2007, the U.S. reduced amenable mortality among men by just 18.5%, while the UK achieved a 36.9% reduction, France 27.7%, and Germany 24.3%. By 2007, the age-standardized death rate from treatable causes among American men under 65 was 68.8 per 100,000, compared to 37.1 in France and 49.5 in Germany. The U.S. was spending more than twice as much per person on healthcare as any of those countries.
Wealth Protects Americans Less Than You’d Think
In both regions, wealthier people live longer. But research from Brown University found that the gap between rich and poor is much wider in the U.S. than in Europe. Americans in the wealthiest quartile have death rates about 40% lower than those in the poorest quartile. In Europe, wealth still matters, but universal healthcare systems and stronger social safety nets compress that gradient.
Perhaps most surprising: even the richest Americans face shorter lifespans than their wealthy European counterparts. The disadvantage isn’t confined to people without insurance or living in poverty. It reaches across the income spectrum, suggesting that systemic factors like gun violence, car-dependent infrastructure, drug policy, and food environments affect everyone, not just the most vulnerable. As one researcher noted, in the U.S. the wealth gap narrows after age 65 partly because the poorest Americans have already died in greater proportion.
What Drives the Difference
No single factor explains the three-year gap. It’s a combination of higher rates of violent death among younger Americans, widespread obesity fueling chronic disease, an expensive healthcare system that leaves treatable conditions untreated for millions, higher infant mortality, and a drug overdose crisis without parallel in Europe. Each of these shaves months or years off the national average, and together they add up to a persistent, significant disadvantage. Researchers at Stanford have argued that targeting the causes of death among younger Americans, particularly gun violence, suicide, motor vehicle crashes, and overdoses, would do more to close the gap than focusing solely on the diseases of old age.